-
- C Kreck, S Bingel, E Heberlein, M Schepping, and U Winkler.
- MDK in Hessen.
- Versicherungsmedizin. 1999 Dec 1;51(4):186-93.
AbstractA growing number of innovative, high-cost drugs call for assessment from social medicine. Synthetic human growth hormone (somatropin, STH) is a prominent example. The use of STH in children greatly increased over the last few years. Treatment extends over years and cost may add up to 30,000 to 70,000 DM/year. STH is licensed for treatment of insufficient secretion of growth hormone, in girls with Ullrich Turner Syndrome and in prepubertal children with chronic renal failure. Off-label use of STH is widespread. The following questions arise: Is STH treatment medically necessary? Must social security (health insurance) carriers pay for STH treatment? Which methods are appropriate to analyse growth and to ascertain growth hormone deficiency? The stated target of STH treatment is a relevant increase of body height. Is this target achieved in the various indications? Special problems arise where psychosocial considerations are put forward.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.